NKTR vs. ADCT, OMER, AVIR, MCRB, ASMB, ALXO, CPIX, PCRX, LLY, and JNJ
Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include ADC Therapeutics (ADCT), Omeros (OMER), Atea Pharmaceuticals (AVIR), Seres Therapeutics (MCRB), Assembly Biosciences (ASMB), ALX Oncology (ALXO), Cumberland Pharmaceuticals (CPIX), Pacira BioSciences (PCRX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceutical preparations" industry.
Nektar Therapeutics (NASDAQ:NKTR) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Nektar Therapeutics received 575 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 70.61% of users gave Nektar Therapeutics an outperform vote while only 65.00% of users gave ADC Therapeutics an outperform vote.
In the previous week, Nektar Therapeutics and Nektar Therapeutics both had 1 articles in the media. ADC Therapeutics' average media sentiment score of 0.65 beat Nektar Therapeutics' score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media.
ADC Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nektar Therapeutics currently has a consensus target price of $3.50, suggesting a potential upside of 181.12%. ADC Therapeutics has a consensus target price of $7.25, suggesting a potential upside of 108.33%. Given Nektar Therapeutics' higher possible upside, equities analysts clearly believe Nektar Therapeutics is more favorable than ADC Therapeutics.
Nektar Therapeutics has a net margin of -195.02% compared to ADC Therapeutics' net margin of -330.17%. Nektar Therapeutics' return on equity of -107.31% beat ADC Therapeutics' return on equity.
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 3.7% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Nektar Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.
Summary
Nektar Therapeutics beats ADC Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Nektar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nektar Therapeutics Competitors List
Related Companies and Tools
